Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 25, 2025, titled "Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received final approval from the USFDA to market Verapamil Hydrochloride Extended-Release Tablets in three strengths: 120 mg, 180 mg, and 240 mg. Verapamil is a generic medication commonly used to treat high blood pressure and certain heart conditions. The approval allows Zydus to manufacture and commercially launch the product in the United States. This adds to Zydus's growing portfolio of US generic drug approvals. The company has a strong track record of USFDA approvals and is one of the larger Indian generic drug exporters to the US market.
Mildly positive for the stock, as new USFDA approvals typically support revenue growth from US operations, though the financial impact of a single generic approval is usually modest given competitive pricing in the segment.